Dopo l’endorsement dei giorni scorsi ricevuto dello staff interno dell’Fda, lo scorso 15 gennaio il nuovo antiaggregante orale vorapaxar ha ricevuto il parere positivo degli esperti del Cardiovascular and Renal Drugs Advisory Committee dell’Fda. Con 10 voti a 1, gli...
Risultati per " trials "
Allopurinol and Cardiovascular Outcomes in Adults With Hypertension
Allopurinol lowers blood pressure in adolescents and has other vasoprotective effects. Whether similar benefits occur in older individuals remains unclear. We hypothesized that allopurinol is associated with improved cardiovascular outcomes in older adults with...
Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease
Journal of the American College of Cardiology Background Although recommended in guidelines for the management of coronary heart disease (CHD), concerns have been raised about the applicability of evidence from existing meta-analyses of exercise-based cardiac...
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Summary Background The benefits of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these effects differ by baseline blood pressure, presence of comorbidities, or drug class is less clear. We...
A NEW DISCOVERY TO DEFINITIVELY REDUCE “BAD” CHOLESTEROL
Amazing! A new vaccine can significantly reduce low-density lipoprotein (LDL) cholesterol (the bad one) in both mice and rhesus macaque monkeys. The study comes from some researchers led by Dr. Bryce Chackerian of the Department of Molecular Genetics and...
SARTANI E RISCHIO DA TUMORE: La Posizione della SIA
Una metanalisi pubblicata da Lancet Oncology aveva evidenziato un possibile modesto aumento di rischio di sviluppare neoplasie nei pazienti in terapia con sartani. Dopo il commento di Mauro Venegoni del Centro regionale Farmacovigilanza di Milano, diamo spazio ai...